CO2018013827A2 - Procesos para preparar oligómeros de morfolino fosforodiamidato - Google Patents

Procesos para preparar oligómeros de morfolino fosforodiamidato

Info

Publication number
CO2018013827A2
CO2018013827A2 CONC2018/0013827A CO2018013827A CO2018013827A2 CO 2018013827 A2 CO2018013827 A2 CO 2018013827A2 CO 2018013827 A CO2018013827 A CO 2018013827A CO 2018013827 A2 CO2018013827 A2 CO 2018013827A2
Authority
CO
Colombia
Prior art keywords
processes
oligomer
preparing
morpholino phosphorodiamidate
preparing morpholino
Prior art date
Application number
CONC2018/0013827A
Other languages
English (en)
Inventor
Bao Cai
Mitchell Martini
Ross Shimabuku
Katie Thomas
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of CO2018013827A2 publication Critical patent/CO2018013827A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a procesos para preparar un oligómero (por ejemplo, un oligómero de morfolino). Los procesos sintéticos descritos en la presente pueden ser ventajosos para el escalar la síntesis de oligómeros mientras se mantiene el rendimiento general y pureza de un oligómero sintetizado.
CONC2018/0013827A 2016-05-24 2018-12-19 Procesos para preparar oligómeros de morfolino fosforodiamidato CO2018013827A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662357134P 2016-06-30 2016-06-30
PCT/US2017/034284 WO2017205513A1 (en) 2016-05-24 2017-05-24 Processes for preparing phosphorodiamidate morpholino oligomers

Publications (1)

Publication Number Publication Date
CO2018013827A2 true CO2018013827A2 (es) 2018-12-28

Family

ID=59078166

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013827A CO2018013827A2 (es) 2016-05-24 2018-12-19 Procesos para preparar oligómeros de morfolino fosforodiamidato

Country Status (26)

Country Link
US (2) US10961262B2 (es)
EP (2) EP3464306B1 (es)
JP (1) JP6987081B2 (es)
KR (1) KR102504759B1 (es)
CN (1) CN109311920B (es)
AU (1) AU2017271524B2 (es)
BR (1) BR112018074270B1 (es)
CA (1) CA3024182A1 (es)
CO (1) CO2018013827A2 (es)
DK (1) DK3464306T3 (es)
FI (1) FI3464306T3 (es)
HR (1) HRP20240583T1 (es)
HU (1) HUE066393T2 (es)
IL (1) IL263033B2 (es)
LT (1) LT3464306T (es)
MA (1) MA45155A (es)
MD (1) MD3464306T2 (es)
MX (1) MX2018014162A (es)
PL (1) PL3464306T3 (es)
PT (1) PT3464306T (es)
RS (1) RS65504B1 (es)
SA (1) SA518400462B1 (es)
SG (1) SG11201809499UA (es)
SI (1) SI3464306T1 (es)
TW (1) TWI737736B (es)
WO (1) WO2017205513A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
FI3464306T3 (fi) 2016-05-24 2024-05-16 Sarepta Therapeutics Inc Menetelmiä fosforodiamidaattimorfolino-oligomeerien valmistamiseksi
MA45362A (fr) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
SG10202101830WA (en) * 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
JP7022079B2 (ja) * 2016-06-30 2022-02-17 サレプタ セラピューティクス， インコーポレイテッド ホスホロジアミダートモルホリノオリゴマーを調製するためのプロセス
KR102523527B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
TWI812647B (zh) * 2017-09-25 2023-08-21 美商薩羅塔治療公司 經由速流合成以製備磷醯二胺嗎啉代寡聚物之製程
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF DYSTROPHINOPATHIES
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
US20230174981A1 (en) * 2020-03-16 2023-06-08 National University Corporation Tokyo Medical And Dental University Heteronucleic acid containing morpholino nucleic acid
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL312142A (en) * 2021-11-01 2024-06-01 Dyne Therapeutics Inc Muscle targeting complexes for the treatment of dystrophinopathy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE171185T1 (de) 1985-03-15 1998-10-15 Antivirals Inc Immunotestmittel für polynukleotid und verfahren
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
AU4225889A (en) 1988-09-01 1990-04-02 Forskningscenter Riso Peptide synthesis method and solid support for use in the method
EP0737193A1 (en) * 1993-12-29 1996-10-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6784291B2 (en) 2000-05-04 2004-08-31 Avi Biopharma, Inc. Splice-region antisense composition and method
CA2459347C (en) 2001-09-04 2012-10-09 Exiqon A/S Locked nucleic acid (lna) compositions and uses thereof
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
WO2004044140A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceticals, Inc. 2’-substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
EP2206781B1 (en) 2004-06-28 2015-12-02 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
BRPI0819828A8 (pt) 2007-11-15 2022-12-27 Avi Biopharma Inc Processo de síntese de oligômeros de morfolino
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
ES2693459T3 (es) 2009-11-12 2018-12-11 The University Of Western Australia Moléculas antisentido y métodos para el tratamiento de patologías
TWI620756B (zh) * 2010-05-28 2018-04-11 薩羅塔治療公司 具有經修飾之單元間連結及／或末端基團之寡核苷酸類似物
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
TWI541024B (zh) * 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN103154009B (zh) 2010-09-30 2015-06-10 日本新药株式会社 吗啉基核酸衍生物
WO2012109296A1 (en) * 2011-02-08 2012-08-16 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Antisense oligonucleotides
WO2013026142A1 (en) 2011-08-23 2013-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
ES2535654T3 (es) 2011-10-13 2015-05-13 Association Institut De Myologie ADN triciclo-fosforotioato
CA2854907C (en) 2011-11-18 2020-03-10 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
ES2727481T3 (es) * 2011-11-30 2019-10-16 Sarepta Therapeutics Inc Inclusión inducida de exón en atrofia muscular espinal
EP2799548B1 (en) * 2011-12-28 2019-08-21 Nippon Shinyaku Co., Ltd. Antisense nucleic acid
WO2013128281A1 (en) 2012-02-28 2013-09-06 Population Genetics Technologies Ltd Method for attaching a counter sequence to a nucleic acid sample
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
MX366274B (es) * 2013-03-14 2019-07-04 Sarepta Therapeutics Inc Composiciones para el salto del exón para el tratamiento de distrofia muscular.
EP3633035A1 (en) * 2013-03-14 2020-04-08 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
US8999152B2 (en) * 2013-03-15 2015-04-07 Uop Llc Process and apparatus for recovering and blending hydroprocessed hydrocarbons and composition
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
CN105228999B (zh) 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
FI3464306T3 (fi) * 2016-05-24 2024-05-16 Sarepta Therapeutics Inc Menetelmiä fosforodiamidaattimorfolino-oligomeerien valmistamiseksi
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
SG10202101830WA (en) 2016-05-24 2021-04-29 Sarepta Therapeutics Inc Processes for preparing oligomers
DK3554553T3 (da) 2016-12-19 2022-09-19 Sarepta Therapeutics Inc Exon-overspringnings-oligomerkonjugat til muskeldystrofi

Also Published As

Publication number Publication date
HUE066393T2 (hu) 2024-07-28
JP2019523754A (ja) 2019-08-29
HRP20240583T1 (hr) 2024-07-19
TWI737736B (zh) 2021-09-01
EP4406600A2 (en) 2024-07-31
AU2017271524B2 (en) 2021-06-24
FI3464306T3 (fi) 2024-05-16
EP3464306A1 (en) 2019-04-10
WO2017205513A1 (en) 2017-11-30
DK3464306T3 (da) 2024-05-21
IL263033A (en) 2018-12-31
MA45155A (fr) 2019-04-10
JP6987081B2 (ja) 2021-12-22
US20190276480A1 (en) 2019-09-12
BR112018074270B1 (pt) 2021-02-02
US20220340605A1 (en) 2022-10-27
US10961262B2 (en) 2021-03-30
SI3464306T1 (sl) 2024-08-30
MD3464306T2 (ro) 2024-08-31
CN109311920B (zh) 2021-11-09
PL3464306T3 (pl) 2024-07-22
EP3464306B1 (en) 2024-03-27
KR102504759B1 (ko) 2023-02-28
SA518400462B1 (ar) 2022-06-12
IL263033B2 (en) 2023-02-01
TW201825506A (zh) 2018-07-16
IL263033B (en) 2022-10-01
CA3024182A1 (en) 2017-11-30
BR112018074270A2 (pt) 2019-03-12
CN109311920A (zh) 2019-02-05
PT3464306T (pt) 2024-05-17
SG11201809499UA (en) 2018-12-28
KR20190013844A (ko) 2019-02-11
MX2018014162A (es) 2019-04-01
RS65504B1 (sr) 2024-06-28
AU2017271524A1 (en) 2018-11-15
LT3464306T (lt) 2024-05-10

Similar Documents

Publication Publication Date Title
CO2018013827A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013834A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013838A2 (es) Procesos para preparar oligómeros
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2019002975A2 (es) Compuestos de tetraciclina y métodos de uso de los mismos
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CO2019006018A2 (es) Polimorfos de sepiapterina y sus sales
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
GT201600091A (es) Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
MX2019000664A (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona.
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
WO2017112809A8 (en) System and method for solution phase gap peptide synthesis
DOP2016000211A (es) Pirazinas moduladoras de gpr6
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
NZ720106A (en) A process for the preparation of regadenoson
CU20190035A7 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
CL2023000942A1 (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso .
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
CL2021000663A1 (es) Proceso para la producción de gas de síntesis.
MX2022001549A (es) Nuevas sintesis telescopicas de 2-metoximetil-p-fenilendiamina.